Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli

Moxalactam (LY127935; 6059S), a new broad-spectrum β-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels wer 100.6 and 35.5 μg/ml, respectively. corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 μg.ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.